Skip to main content

Table 1 Patient baseline characteristics

From: Stereotactic body radiotherapy with periprostatic hydrogel spacer for localized prostate cancer: toxicity profile and early oncologic outcomes

Age ± stdev, y 69±7.5
 Range, y 50-82
PSA ± stdev, ng/mL 7.4±3.2
 Range, ng/mL 2.7-19.5
Gleason score 6 8 (16%)
Gleason score 7 42 (84%)
 Primary GS 4 19 (38%)
Cores involved ± stdev (#) 4.1±2.4
 Range 1-11
Cores involved ± stdev (%) 32±18
 Range 8-80
Clinical T stage:
 cT1c, % 86
 cT2a, % 12
 cT2b, % 2
NCCN Risk Stage
 Low 8 (16%)
 Intermediate, favorable 16 (32%)
 Intermediate, unfavorable 26 (52%)
AUA score ± stdev 9±7
 Range 0-25
SHIM score ± stdev 13±8.5
 Range 0-26
Prostate volume ± stdev (cc) 63±28
 Range 30-109